Skip to main content
Year archive

Alligator Bioscience — 2024 filings

All 66 regulatory filings released by Alligator Bioscience (ATORX) in 2024, sourced directly from the official regulator.

66 Filings
2024 Period
2024 filings (66)
Filing Released Lang
Ändring av antalet aktier och röster i Alligator Bioscience
Declaration of Voting Results & Voting Rights Announcements
2024-12-30 Swedish
Change in number of shares and votes in Alligator Bioscience
Declaration of Voting Results & Voting Rights Announcements
2024-12-30 English
Alligator Bioscience AB announces outcome of exercise of warrants series TO 9
Capital/Financing Update
2024-12-20 English
Alligator Bioscience AB meddelar utfall för nyttjandet av teckningsoptioner serie TO 9
Capital/Financing Update
2024-12-20 Swedish
Last day of trading in warrants series TO 9 in Alligator Bioscience AB is 13 December 2024
Capital/Financing Update
2024-12-13 English
Sista dag för handel med teckningsoptioner serie TO 9 i Alligator Bioscience AB är den 13 december 2024
Share Issue/Capital Change
2024-12-13 Swedish
Alligator Bioscience publicerar finansiell kalender för 2025
Report Publication Announcement
2024-12-04 Swedish
Alligator Bioscience publishes financial calendar for 2025
Report Publication Announcement
2024-12-04 English
Alligator Bioscience resolves on conversion of series C shares into ordinary shares for delivery to participants in incentive program
Share Issue/Capital Change
2024-12-03 English
Alligator Bioscience beslutar om omvandling av C-aktier till stamaktier för leverans till deltagare i incitamentsprogram
Share Issue/Capital Change
2024-12-03 Swedish
Teckningskurs fastställd för nyttjandet av teckningsoptioner serie TO 9 i Alligator Bioscience AB
Share Issue/Capital Change
2024-12-02 Swedish
Exercise price determined for the exercise of warrants series TO 9 in Alligator Bioscience AB
Capital/Financing Update
2024-12-02 English
Notice of extraordinary general meeting in Alligator Bioscience AB
AGM Information
2024-12-02 English
Kallelse till extra bolagsstämma i Alligator Bioscience AB
AGM Information
2024-12-02 Swedish
Alligator sharpens focus on mitazalimab and announces cost reduction program to maximize long-term value creation
Regulatory Filings
2024-12-02 English
Alligator Bioscience genomför en företrädesemission av units om cirka 280 MSEK samt upptar brygglån
Capital/Financing Update
2024-12-02 Swedish
Alligator Bioscience carries out a rights issue of units of approximately SEK 280 million and raises bridge loans
Capital/Financing Update
2024-12-02 English
Alligator skärper fokus på mitazalimab och planerar omstrukturering för att förstärka den långsiktiga värdeskapande förmågan
Regulatory Filings
2024-12-02 Swedish
Alligator announces sale of future financial commitments for two bispecific antibodies to Orion Corporation
Capital/Financing Update
2024-11-19 English
Alligator säljer rätten till framtida finansiella åtaganden för två bispecifika antikroppar till Orion Corporation
Regulatory Filings
2024-11-19 Swedish
Nomination Committee appointed in respect of AGM 2025 in Alligator Bioscience AB
AGM Information
2024-10-31 English
Valberedning utsedd inför årsstämma 2025 i Alligator Bioscience AB
Governance Information
2024-10-31 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report 9M 2024
2024-10-24 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report 9M 2024
2024-10-24 English
Interim / Quarterly Report 2024
Interim / Quarterly Report H1 2024
2024-07-11 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report H1 2024
2024-07-11 English
Alligator Bioscience meddelar omfattande överlevnadsfördelar och en oöverträffad Duration of Response vid 18 månaders-analysen från fas 2-studien OPTIMIZE-1 med mitazalimab i bukspottkörtelcancer
Earnings Release FY 2024
2024-06-26 Swedish
Alligator Bioscience Announces Substantial Overall Survival Benefit and Unprecedented Duration of Response in the 18-Month Analysis from Mitazalimab OPTIMIZE-1 Phase 2 Study in 1st Line Pancreatic Can
Regulatory Filings
2024-06-26 English
Alligator Bioscience announces financing of up to SEK 80 million extending cash runway to Q1 2025
Capital/Financing Update
2024-06-25 English
Alligator Bioscience offentliggör finansiering om upp till 80 MSEK som förlänger kassalikviditet till Q1 2025
Capital/Financing Update
2024-06-25 Swedish
Alligator Bioscience Apppoints Johan Giléus as Chief Financial Officer
Board/Management Information
2024-06-14 English
Alligator Bioscience utser Johan Giléus till Chief Financial Officer
Board/Management Information
2024-06-14 Swedish
Bulletin from the annual general meeting in Alligator Bioscience AB on 7 May 2024
AGM Information
2024-05-07 English
Kommuniké från årsstämma den 7 maj 2024 i Alligator Bioscience AB
AGM Information
2024-05-07 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Q1 2024
2024-05-06 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Q1 2024
2024-05-06 English
Change in number of shares and votes in Alligator Bioscience AB
Declaration of Voting Results & Voting Rights Announcements
2024-04-30 English
Ändring av antalet aktier och röster i Alligator Bioscience AB
Declaration of Voting Results & Voting Rights Announcements
2024-04-30 Swedish
Alligator Bioscience and Orion Corporation announce exercise of development option under 2021 Immuno-oncology Research Collaboration and License Agreement
Capital/Financing Update
2024-04-26 English
Alligator Bioscience och Orion Corporation meddelar att utvecklingsmöjlighet nyttjats inom bolagens immunonkologiska forskningssamarbete och licensavtal från 2021
Regulatory Filings
2024-04-26 Swedish
Major Shareholding Notification 2024
Major Shareholding Notification
2024-04-25 English
Last day of trading in paid subscribed units (Sw. BTU) in Alligator
Share Issue/Capital Change
2024-04-18 English
Sista dag för handel med BTU i Alligator
Capital/Financing Update
2024-04-18 Swedish
Alligator publishes outcome in rights issue
Capital/Financing Update
2024-04-09 English
Alligator offentliggör utfall i företrädesemission
Capital/Financing Update
2024-04-09 Swedish
Notice of annual general meeting in Alligator Bioscience AB
AGM Information
2024-04-05 English
Kallelse till årsstämma i Alligator Bioscience AB
AGM Information
2024-04-05 Swedish
Alligator publishes supplementary prospectus
Report Publication Announcement
2024-03-22 English
Alligator offentliggör tilläggsprospekt
Capital/Financing Update
2024-03-22 Swedish
Annual Report (ESEF) 2023
Annual Report (ESEF) FY 2023
2024-03-21 Swedish
The subscription period in Alligator Bioscience’s rights issue begins today
Share Issue/Capital Change
2024-03-21 English
Idag börjar teckningstiden för Alligator Biosciences företrädesemission
Share Issue/Capital Change
2024-03-21 Swedish
Alligator Bioscience publishes prospectus in connection with forthcoming rights issue
Capital/Financing Update
2024-03-15 English
Alligator Bioscience offentliggör prospekt med anledning av förestående företrädesemission
Capital/Financing Update
2024-03-15 Swedish
Bulletin from the extraordinary general meeting in Alligator Bioscience AB
AGM Information
2024-03-14 English
Kommuniké från extra bolagsstämma i Alligator Bioscience AB
AGM Information
2024-03-14 Swedish
Kallelse till extra bolagsstämma i Alligator Bioscience AB
AGM Information
2024-02-08 Swedish
Notice of extraordinary general meeting in Alligator Bioscience AB
AGM Information
2024-02-08 English
Alligator carries out a rights issue of units of approximately SEK 150.9 million with an over-allotment issue of up to an additional approximately SEK 100.0 million and raises bridge loans
Capital/Financing Update
2024-02-08 English
Alligator genomför en företrädesemission av units om cirka 150,9 MSEK med övertilldelningsemission om upp till ytterligare cirka 100,0 MSEK samt upptar brygglån
Capital/Financing Update
2024-02-08 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Q4 2023
2024-02-08 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Q4 2023
2024-02-08 English
Alligator Bioscience Announces Cost Reduction Program to Align Key Priorities and Maximize Long-Term Value Creation
Regulatory Filings
2024-02-08 English
Alligator Bioscience planerar omstrukturering för att fokusera resurser på sina viktigaste prioriteringar och stärka den långsiktiga konkurrenskraften
Regulatory Filings
2024-02-08 Swedish
Alligator Bioscience meddelar positiva fas-2 resultat i OPTIMIZE-1 med Mitazalimab, där man både uppfyller primärt effektmått och ger kliniskt relevanta överlevnadsfördelar
Earnings Release FY 2024
2024-01-29 Swedish
Alligator Bioscience Announces Positive Mitazalimab OPTIMIZE-1 Phase 2 Results Meeting Primary Endpoint and Demonstrating Clinically Relevant Survival Benefits in 1st Line Pancreatic Cancer
Earnings Release FY 2024
2024-01-29 English